Anavex Life Sciences’ (AVXL) Buy Rating Reaffirmed at Noble Financial
AVXL has been the topic of several other research reports. Maxim Group set a $5.00 price objective on shares of Anavex Life Sciences and gave the stock a buy rating in a research note on Wednesday, February 14th. ValuEngine cut shares of Anavex Life Sciences from a hold rating to a sell rating in a research note on Tuesday, November 21st.
Anavex Life Sciences (NASDAQ AVXL) opened at $2.52 on Wednesday. Anavex Life Sciences has a one year low of $2.45 and a one year high of $6.49.
Several large investors have recently modified their holdings of the company. Vanguard Group Inc. lifted its stake in shares of Anavex Life Sciences by 8.9% in the 2nd quarter. Vanguard Group Inc. now owns 1,617,757 shares of the biotechnology company’s stock worth $8,606,000 after purchasing an additional 132,076 shares during the period. State Street Corp increased its holdings in Anavex Life Sciences by 15.2% in the 2nd quarter. State Street Corp now owns 603,326 shares of the biotechnology company’s stock worth $3,210,000 after acquiring an additional 79,516 shares in the last quarter. Northern Trust Corp increased its holdings in Anavex Life Sciences by 16.0% in the 2nd quarter. Northern Trust Corp now owns 429,073 shares of the biotechnology company’s stock worth $2,282,000 after acquiring an additional 59,069 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in Anavex Life Sciences by 60.3% in the 4th quarter. Bank of New York Mellon Corp now owns 177,938 shares of the biotechnology company’s stock worth $573,000 after acquiring an additional 66,931 shares in the last quarter. Finally, Deutsche Bank AG increased its holdings in Anavex Life Sciences by 150.9% in the 4th quarter. Deutsche Bank AG now owns 82,967 shares of the biotechnology company’s stock worth $266,000 after acquiring an additional 49,904 shares in the last quarter. Hedge funds and other institutional investors own 22.68% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This article was first posted by Daily Political and is the sole property of of Daily Political. If you are viewing this article on another publication, it was stolen and reposted in violation of US and international copyright law. The original version of this article can be viewed at https://www.dailypolitical.com/2018/02/22/anavex-life-sciences-avxl-buy-rating-reaffirmed-at-noble-financial.html.
About Anavex Life Sciences
Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases.
Receive News & Ratings for Anavex Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.